Viewing Study NCT00671112


Ignite Creation Date: 2025-12-26 @ 10:46 PM
Ignite Modification Date: 2026-05-22 @ 1:08 PM
Study NCT ID: NCT00671112
Status: TERMINATED
Last Update Posted: 2015-10-28
First Post: 2008-05-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Sponsor: Brian Hill, MD, PhD
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None 714leukemia View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None recurrent grade 1 follicular lymphoma View
None recurrent grade 2 follicular lymphoma View
None recurrent grade 3 follicular lymphoma View
None recurrent mantle cell lymphoma View
None recurrent marginal zone lymphoma View
None recurrent small lymphocytic lymphoma View
None Waldenstrom's macroglobulinemia View
None extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue View
None nodal marginal zone B-cell lymphoma View
None splenic marginal zone lymphoma View
None refractory hairy cell leukemia View
None B-cell chronic lymphocytic leukemia View
None refractory chronic lymphocytic leukemia View
None hairy cell leukemia View
None cutaneous B and T cell lymphoma View
None transformed lymphoma View
None transformed B and T cell cutaneous lymphoma View
None relapsed or refractory diffuse large B cell lymphoma View
None extranodal T cell lymphomas View
None anaplastic large cell lymphoma View
None angioimmunoblastic T cell lymphoma View
None PTCL-NOS View
None nasal or disseminated extranodal T/NK lymphoma View
None enteropathy-associated T cell lymphoma View
None hepatosplenic gamma/delta T cell lymphoma View
None subcutaneous panniculitis-like T cell lymphoma View
None T-prolymphocytic leukemia View
None adult T-cell leukemia/lymphoma View
None large granular lymphocytic leukemia View
None aggressive NK leukemia View